Glby, Encoded by MAB_3167c, Is Required for In Vivo Growth of Mycobacteroides abscessus and Exhibits Mild β-Lactamase Activity

Christos Galanis, Emily C. Maggioncalda, Pankaj Kumar, Gyanu Lamichhane

Center for Tuberculosis Research, Department of Medicine, School of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

ABSTRACT Mycobacteroides abscessus (Mab; also known as Mycobacterium abscessus) is an emerging opportunistic pathogen. Patients with structural lung conditions such as bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease are at high risk of developing pulmonary Mab disease. This disease is often chronic as the current treatment regimens are sub-efficacious. Here, we characterize the phenotype of a Mab strain lacking the MAB_3167c locus, which encodes a protein hereafter referred to as Glby. We demonstrate that the loss of Glby impairs normal planktonic growth in liquid broth, results in longer average cell length, and a melding of surfaces between cells. Glby also exhibits a mild β-lactamase activity. We also present evidence that amino acid substitutions that potentially alter Glby function are not favored. Lastly, we demonstrate that, in a mouse model of pulmonary Mab infection, the mutant lacking Glby was unable to proliferate, gradually cleared, and was undetectable after 3 weeks. These data suggest that an agent that inhibits Glby in vivo may be an efficacious treatment against Mab disease.

IMPORTANCE Mycobacteroides abscessus can cause chronic pulmonary infections requiring administration of multiple antibiotics, still resulting in a low cure rate. The incidence of M. abscessus disease is increasing in the United States and the developed regions of the world. We show for the first time that a protein, Glby, affects growth of this bacterium. Using a mouse model of lung M. abscessus disease, we demonstrate that Glby is required for this bacterium to cause disease.

KEYWORDS MAB_3167c, Glby, β-lactamase, Mycobacterium abscessus, Mycobacteroides abscessus

Mycobacteroides abscessus (Mab) is a rapidly growing non-tuberculous mycobacterium. It is an opportunistic pathogen that can cause chronic infections with incidences predominantly in patients with structural lung conditions such as bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease (1–3). In cystic fibrosis patients, Mab is one of the most frequently isolated non-tuberculous mycobacteria (4–7). Additionally, Mab soft tissue infections in cosmetic surgery patients have also been reported (8, 9).

Mab is considered an emerging pathogen whose incidence in the U.S. is rising (10). Mab infection can be acquired from the environment, from infected individuals or via fomite intermediates (11–16). A recent report declared Mab “an environmental bacterium turned clinical nightmare” (17) citing the following reasons: (i) Mab disease is associated with rapid lung function decline and is often incurable (5, 18, 19); (ii) there are no FDA approved drugs to treat Mab disease, and the cure rate with the current treatment regimens, which are based on repurposed antibiotics that need to be taken daily for at least 1 year, is only 30% to 50% (20); and (iii) Mab is intrinsically resistant to most antibiotics used today to treat Mab disease (21, 22). To make matters worse, a number of antibiotics from this limited selection are associated with frequent toxicities...
(23). Current guidelines for treating Mab disease are based on clinical experience on repurposing antibiotics, as regimens informed from a clinical trial have yet to be developed (24, 25). Despite the increasing incidence of this disease, there are critical knowledge gaps in the fundamental biology of this unique microbe, which, as emerging evidence suggests, is distinct in many ways from the mycobacteria genus.

A fundamental component of bacterial cell walls is its peptidoglycan. It is the exoskeleton of bacterial cells and is required for their viability, cellular growth, and division. A major class of proteins that is involved in the final step of peptidoglycan synthesis in bacteria are D,D-transpeptidases that catalyze formation of transpeptide linkages between the fourth amino acid of one stem peptide and the third amino acid of another stem peptide (26, 27). This class of proteins is also commonly referred to as penicillin binding protein (PBP) as they were discovered as proteins that bind to penicillins. Subsequent studies revealed that this class includes proteins with D,D-transpeptidase and/or transglycosylase and D,D-carboxypeptidase activities (26). Therefore, the term PBP is a historical relic and does not capture the activities most relevant to cell wall biosynthesis and metabolism and only signifies their ability to bind to penicillins. In this study, only those proteins in Mab with homology to Mycobacterium tuberculosis proteins with D,D-transpeptidase, transglycosylase and D,D-carboxypeptidase activity were of interest. Additionally, the pathway for peptidoglycan synthesis is enriched in genes essential for bacterial viability, and mimics of metabolites generated in this pathway exhibit antimycobacterial activity (28). The relevance of these proteins in Mab to its viability, virulence, and cellular physiology has not yet been directly described.

Although the core genome content of Mab has a deep ancestral branching point off from other mycobacteria spp. (29), the well-characterized genome of M. tuberculosis has many conserved features when compared with Mab. The M. tuberculosis genome encodes for 10 putative D,D-transpeptidases/transglycosylases and D,D-carboxypeptidases (30–32). The D,D-transpeptidases are involved in synthesis of peptidoglycan whereas the D,D-carboxypeptidases catalyze removal of terminal amino acid from peptidoglycan sidechains (33). The following five M. tuberculosis proteins belong to the D,D-transpeptidases class: PbpA (Rv0016c), PbpB (Rv2163c), Pbp-lipo (Rv2864c), PonA1 (Rv0050), and PonA2 (Rv3682). The amino acid sequences of these proteins were used as a template to identify five homologs in Mab, of which the strain lacking MAB_3167c demonstrated a distinct phenotype in liquid culture, and therefore is the subject of this study. We note that the sequence homologs of M. tuberculosis D,D-transpeptidases in Mab are only presumed to be putative D,D-transpeptidases. In reference to the “globular” appearance of this mutant in culture, and implications of this phenotype to the physiology of Mab which is described below, MAB_3167c is hereafter referred to as glob (Globby). We investigated the relevance of glob to Mab growth in standard laboratory media, cellular morphology, enzymatic activity against a β-lactam reporter, and viability and growth in a mouse model of pulmonary Mab disease.

RESULTS

Globy’s amino acid sequence is highly conserved in Mab clinical isolates. We used the five proteins of M. tuberculosis belonging to the D,D-transpeptidase class, PbpA (Rv0016c), PbpB (Rv2163c), Pbp-lipo (Rv2864c), PonA1 (Rv0050), and PonA2 (Rv3682), as templates to identify homologs in Mab. They are MAB_0035c, MAB_0408c, MAB_2000, MAB_3167c, and MAB_4901c, respectively. Multiple attempts to generate Mab strains with deletion of MAB_0035c and MAB_2000 did not yield any colonies. We were able to generate Mab strains lacking MAB_0408c, MAB_3167c, and MAB_4901c. Growth and colony morphology phenotypes of Mab lacking MAB_0408c or MAB_4901c were unremarkable compared with the parent strain. Mab lacking MAB_3167c exhibited a distinct growth phenotype (described below) and therefore was considered for further study.

Mab isolates recovered from patients display significant genomic heterogeneity and differences in antibacterial susceptibility profiles, indicating that most of the clinical isolates represent a non-clonal collection (34). It has been previously established in multiple genome wide
TABLE 1 Distribution of I509V mutation in Glby in 1,046 Mab clinical isolates

| Country       | # of isolates | # of isolates with I509V mutation (%) |
|---------------|---------------|---------------------------------------|
| United Kingdom| 495           | 107 (22%)                             |
| China         | 275           | 68 (25%)                              |
| United States | 165           | 42 (25%)                              |
| Australia     | 72            | 4 (6%)                                |
| Malaysia      | 12            | 8 (67%)                               |
| Denmark       | 9             | 1 (11%)                               |
| Brazil        | 6             | 5 (83%)                               |
| France        | 6             | 2 (33%)                               |
| South Korea   | 3             | 2 (67%)                               |
| Ireland       | 3             | 1 (33%)                               |
| **Total**     | **1,046**     | **240 (22%)**                         |

Glby is Required for M. abscessus Disease

Association studies across different species of bacteria and different organisms that regions containing vital sequences for organism survival are more likely to be conserved, as mutations that significantly alter the sequence, often lead to a loss of fitness (35–37). We therefore hypothesized that if glby is necessary for infection, any amino acid mutations would likely be deselected for in a collection of clinical isolates. We analyzed the glby locus (MAB_3167c) in the genomes of 1,046 independent clinical isolates from across the world that are archived in the publicly accessible database PATRIC (38) and built the consensus sequence for this gene (Fig. S1). This database included origins of the isolates, which permitted analysis of genomic variations in different regions of the world (Table 1). Of the 110 SNP locations, only 18 resulted in an amino acid substitution (83.6% were silent mutations) and only one of those (1525A→G) was present in more than 5% of 1,046 strains (Fig. 1). This substitution results in a conservative missense mutation from an isoleucine to a valine, I509V, which was present in 240 isolates (22%) and was not endemic to a particular geographic region, suggesting independent evolution likely arising from selective pressure. For the countries that had enough representation, only Australia had a low percentage (6%) of isolates that harbor this mutation compared with the United Kingdom (22%), the United States (25%), and China (25%). The remaining countries did not have an adequate number of isolates to enable a statistically accurate representation of isolates that harbor this mutation. The second most prevalent amino acid substitution (49 isolates or 4.6% of 1,046 isolates) is also a conservative missense mutation, A78V, resulting from 233C→T. Because the most prevalent amino acid substitutions (I509V and A78V) are conservative substitutions that are considered to produce little or no change in protein function, these results demonstrate that there is evidence of selective pressure against changes in the amino acid sequence that may compromise Glby function. To further investigate if this selective pressure was specific to glby or a random event that would also affect other genes in the locus, we applied the same bioinformatic approach and assessed mutations in 10 genes upstream and 10 genes downstream of glby (MAB_3157c – MAB_3177) in the genomes of the 1,046 Mab clinical isolates. The frequency of mutations that resulted in amino acid substitutions was significantly lower in glby compared with that in the proximal region (P-value <0.0001) (Fig. S2, Table S1). As this difference cannot be attributed to random chance alone, this evidence suggests that there may be selective pressure against mutations with potentially deleterious effect on Glby function.

Mab lacking glby exhibits altered growth and morphology in vitro. We used Mab ATCC 19977 (hereafter referred to as wild-type, WT), as the parent strain, as it is commonly used as a laboratory reference strain (39). We generated a strain lacking glby (hereafter referred to as Δglby) using a recombinering system optimized for mycobacteria (40). The genome of Δglby was sequenced and compared to the parent WT genome to confirm the deletion of glby and to verify the lack of mutations elsewhere in the genome (Fig. S3). We generated a complemented strain by inserting a copy of glby cloned from WT into the L5 attB site of the Δglby chromosome (attB:pMH94apra-MAB_3167c) (Fig. S4), using plasmid pMH94 (41) with modifications to carry an apramycin selection cassette. The genotype of

May 2022 Volume 204 Issue 5 10.1128/jb.00046-22
Glby is Required for M. abscessus Disease

![FIG 1 Frequencies of mutations in glby in 1,046 M. abscessus clinical isolates. Top-panel: frequencies of all single nucleotide polymorphisms. Bottom-panel: frequencies of SNPs that resulted in amino acid substitutions in Glby. Each bar represents mutation at the specified location. FtsI/PBP represents the predicted functional/catalytic domain characteristic of PBPs.](image)

This strain and the site of glby integration was also verified by sequencing its genome (Fig. S5). This strain is hereafter referred to as COMP. On Middlebrook 7H10 agar base, compared to WT and COMP, Δglby required ~ 2 additional days to form colonies. The colony morphotype, as assessed by gross visualization of the surface architecture, namely, color and size of colonies on Middlebrook 7H10 agar, was not distinct between Δglby and that of the WT and COMP strains (Fig. S6). However, when grown in Middlebrook 7H9 liquid broth, Δglby exhibited a distinct growth morphotype. Δglby grew as a single globular clump during exponential phase while the broth remained clear, whereas WT and COMP grew planktonically and turned the broth turbid (Fig. 2A). Owing to the globular appearance of this strain in liquid broth, we assigned the gene locus (MAB_3167c) a phenotype-based annotation: glby (globby). The reversion of the globular growth phenotype to planktonic growth in the COMP strain demonstrates that this phenotype resulted from the lack of glby. Interestingly, initial growth of Δglby is only permissible in a globular form as ascertained from two distinct experiments. First, we subjected Δglby to incremental sheer forces when growing in liquid broth by altering the diameter of the culture vessel, while maintaining orbital shaking speed constant at 200 revolutions per minute (RPM). When grown in a tube with 1.5 cm diameter (14 mL culture tube, Falcon), Δglby grew as a large single globular clump. In a tube with 3 cm diameter (50 mL culture tube, Falcon), Δglby grew in several (~ 20 to 30) smaller clumps, and, in a 150 mL flask with a 6 cm diameter, Δglby failed to grow for 5 days, but formed one large clump after 3 days when the shaking speed was lowered to 75 RPM. In the second experiment, we tested the hypothesis that Δglby requires a clumped morphotype to sustain growth in liquid broth. We dispersed a Δglby culture in exponential growth phase with vigorous shaking and pipetting into a planktonic suspension and incubated it at standard growth conditions of 37°C and 200 RPM orbital shaking. Δglby again formed globular clumps within 24 h of dispersal and the broth was clear, demonstrating that clumped growth is preferred over planktonic growth in the absence of glby. Based on the altered growth phenotype in liquid culture, we hypothesized that the generation time (the time it takes for CFU to double) of Δglby may be different compared with that of WT. To test this hypothesis, Δglby, WT, and COMP strains were grown under identical conditions.
and culture optical density (OD) and CFU were determined at regular intervals over 8 days duration (Fig. 2B and C). Importantly, because of ΔgilbY’s globular morphology, OD readings would be inaccurate if not dispersed into planktonic suspension. In addition, the OD determinations would likewise be inaccurate if culture from the same tube was sampled at each successive time point as these interventions may disturb the natural course of ΔgilbY growth. Therefore, four culture tubes per time point per strain were included, and each sample tube was used only once for OD and CFU determination. ΔgilbY exhibited attenuated growth compared with WT and COMP in both OD and CFU determinations (Fig. 2B and C). In the OD measurement assay, ΔgilbY reached peak OD within 72 h, whereas WT and COMP strains reached peak OD within 72 h. Interestingly, when ΔgilbY reaches an OD of ~4 to 5 at about 120 h of growth, which also coincides with the time point at which it reaches peak CFU density, the broth began turning turbid, as it appeared ΔgilbY was sloughing off the clumps. At this time, ΔgilbY existed in both clumped and suspension forms.

When the growth profile of ΔgilbY was compared with WT and COMP in terms of CFU, a clear distinction emerged from the onset of growth until peak, with the largest difference happening at the 48-h time point, at which, CFU density of ΔgilbY was ~1.5 log10 lower compared with WT and COMP strains (Fig. 2C). While WT and COMP attained peak CFU density by 72 h, ΔgilbY required an additional 48 h (120 h time point) to reach the same peak CFU. Of note, ΔgilbY appeared to exhibit bi-phasic rates during the exponential stage, with a higher rate of growth between 0 h and 48 h and a reduced rate thereafter, until peaking at 120 h (Fig. 2D).
In summary, these findings demonstrate that *gIby* is required for growth in planktonic form and for normal growth rate; however, it is dispensable for viability or growth of *Mab*.

An unbiased query based on pairwise sequence alignment of *Glby*’s amino acid sequence using BLAST (42) identified a *M. tuberculosis* protein encoded by *Rv2864c*, with the highest similarity (64% amino acid sequence identity, 78% sequence positivity, e-value = 0). This protein is presumed to be a PBP-lipo and is predicted to encode a PBP with a putative lipoprotein attachment function in the cell wall (30, 43). Because composition of cell wall lipids determines whether various cell wall specific dyes used to probe identities of bacteria can bind and be retained, we asked whether loss of *Glby* affects the cell wall lipid composition using Ziehl-Neelsen (ZN) stain. This dye stains mycobacteria pink (44). If the cell wall lipid composition is affected and the ZN dye is not retained after wash with destain solution, and the counter dye methylene blue is retained, cells instead appear blue. We hypothesized that *D*<sup>glby</sup> cells may have an altered mycolipid layer and consequently exhibit altered staining with the ZN dye. We tested this hypothesis by staining WT, *ΔgIby*, and COMP cells at exponential growth phase with ZN. Both WT and COMP along with the majority of *D*<sup>glby</sup> cells appear pink (Fig. S7). A minority of *D*<sup>glby</sup> cells appeared blue, we conclude that *D*<sup>glby</sup> culture consists of two populations of cells in terms of their ZN staining properties.

To further investigate this finding, we stained WT, *ΔgIby*, and COMP cells with Auramine-rhodamine (AR), a fluorescent dye that is also used in microbiological identification of mycobacteria and is considered more sensitive than ZN (45). The AR compound strongly binds to mycolipids and is not efficiently washed off by the destain solution. Therefore, if the mycolipid layer is compromised, the cells will not appear fluorescent. The intensities of fluorescence were similar among the three strains, (Fig. S8), indicating that the absence of *Glby* does not affect the AR staining properties of *Mab*.

Next, we used scanning electron microscopy to investigate the cellular appearances of WT, *gIby*, and COMP cells. *gIby* cells exhibited two distinct cell morphotypes. First, on average, *gIby* cells were ~300 nm longer than WT or COMP cells (n = 250 cells, P-value < 0.0001) (Fig. 3, Table S2). There were also many outliers from each strain; however, the majority of *gIby* cells were consistently longer than WT or COMP cells with some over 4 μm (Fig. S9).

The second notable difference is the melding of cell surfaces of *gIby* cells which occurred at a higher rate than in WT and COMP cells and between more than two cells (Fig. 4). Surface melding occurred in 21.4% of *gIby* cells, whereas these occurrences were observed in 4.1% and 3.5% of WT and COMP cells, respectively (Table S3). Also, melding among more than two cells occurred frequently in *gIby*, with a maximum of...
11 cells melded together in a single clump, whereas WT and COMP cells exhibited melding between two cells only. The melding is characterized by the presence of an extracellular matrix sandwiched between the surfaces of two cells and observable as mass of light density. Often, this matrix appeared to be making physical contact between the surfaces of two or more cells and stretching along the axis perpendicular to the length of contact surface. Melding was not restricted to a specific region of the cell, rather we observed melding between two poles, between a pole of one cell and lateral surface of another or between lateral surfaces of two cells. Interestingly, cell-cell
molding was most frequently observed in shorter cells as opposed to the longer cells that did not show this multi-point, multi-cell melding in our data set.

**Giby exhibits mild β-lactamase activity.** The C-terminus of *M. tuberculosis* protein Rv2864c harbors a predicted FtsI domain, the presence of which classifies it as a putative PBP (46). As Giby also possesses the same putative FtsI domain, we hypothesized that Giby may also bind to β-lactams as may be expected from proteins with an FtsI domain. This activity is unrelated to the native cellular function of Giby which is likely to be associated with biosynthesis or metabolism of the cell wall. To test this hypothesis, *blac* was overexpressed using pET28a+TEV specifically to avoid any β-lactamase activity arising from proteins expressed from the backbone of the plasmid, such as β-lactamases that are commonly used for selection when cloning. pET28a+TEV harbors a kanamycin resistance marker for selection and is devoid of any β-lactamase encoding gene. Giby was purified to homogeneity (Fig. S10), and we assessed its ability to bind and hydrolyze a chromogenic β-lactam, nitrocefin. This is one of many validated assays for assessing if a protein can bind and metabolize compounds belonging to the β-lactam class, which includes penicillins, cephalosporins, carbapenems, etc. (47, 48). We included two negative control proteins, RAD6 (*Saccharomyces cerevisiae*) and Ubiquitin (human) and as a positive control, we included a β-lactamase, BlaC, of *M. tuberculosis* that is known to rapidly hydrolyze β-lactams (49, 50). All proteins were individually incubated with 100 μM nitrocefin. BlaC reached a rate of nitrocefin hydrolysis of 22.9 μM/min whereas Giby hydrolyzed nitrocefin at a rate of only 0.14 μM/min (Fig. 5). As such, BlaC was able to reach maximum hydrolysis of nitrocefin within 2 min, whereas Giby was able to reach maximum hydrolysis in 5 h and only reached levels about half of BlaC. RAD6 and ubiquitin failed to hydrolyze nitrocefin.

**Giby is essential for in vivo viability and proliferation in mouse lungs.** Next, we asked if Giby is required for *Mab* to produce a productive infection and disease in a mouse model of pulmonary *Mab* infection. As lung infections are the most commonly reported condition in patients diagnosed with *Mab* disease (1, 8), a mammalian model of lung *Mab* infection would permit assessment of whether Giby is required for *Mab* to survive and proliferate in the lungs. It has been recently demonstrated in a mouse model of pulmonary *Mab* infection that the parent strain of ∆*giby* (*Mab* strain ATCC 19977) proliferates in the lungs, produces pathology similar to that in humans, and mimics the response to antibiotics used to treat *Mab* lung infections in humans (51, 52). We used this preclinical mouse model of pulmonary *Mab* infection as our in vivo model.
model of pulmonary Mab infection to investigate whether Δglby can survive and proliferate in the lungs and included WT and COMP as comparator controls.

As it is necessary to grow these strains in vitro to generate a suspension with which to infect mice, and Δglby growth in culture broth does not mimic its parent strain, we performed a pilot study to determine the optimal infection dose of Δglby required to match the implantation CFU of WT and COMP strains. Although Δglby was dispersed prior to infection, it implanted at 10x lower levels than WT and COMP strains in the lungs of mice (Fig. S11). Based on this finding, it was necessary to increase the inoculum of Δglby by 50x so that following its aerosolization, Δglby would implant in the lungs of mice at a burden no less than that of WT and COMP. At 24 h following infection, the lung burdens of Δglby, WT and COMP strains were 3.7 log_{10}, 2.9 log_{10} and 3.1 log_{10}, respectively. While the lung burdens of WT and COMP remained steady during the first week, by the third week there was ~2 log_{10} increase in their CFU in the lungs of mice (Fig. 6, Table S4). However, the lung burden of Δglby steadily decreased from the day of implantation. By week 2, 99.6% of Δglby had been cleared from the lungs of mice; by contrast WT CFU burden in the lungs increased as previously demonstrated (51) and had a final increase in bacterial burden of 2 log_{10} over the implantation level. By the 3-week time point, Δglby CFU was undetectable on growth medium inoculated with the entire lung homogenates from all five mice to detect any surviving Mab. At the 4-week time point, we were again unable to detect any Δglby in the lungs of mice, while WT maintained its CFU level and COMP exhibited a slight decrease, but within the standard deviation of WT CFU levels. As Δglby not only failed to proliferate in the lungs of mice at any time during the study period, but instead was steadily cleared to undetectable levels, we conclude that Glby is required for Mab viability, growth and proliferation in the lungs of C3HeB/FeJ mice. In the study that originally reported this mouse model, the mice eventually succumbed to death from pathology resulting from the WT strain (51). As immunocompromised mice were able to clear Δglby from their lungs, it suggests that Glby is also required for virulence of Mab to cause lung disease.

**DISCUSSION**

The significance of the peptidoglycan biosynthesis pathway to bacteria is underscored by its requirement for viability, growth, and division (26, 53). Considered the Achille’s Heel in bacterial cell physiology, agents that inhibit the peptidoglycan biosynthesis pathway, namely, β-lactams and glycopeptides, comprise more than half of all antibiotics prescribed to treat bacterial infections in humans (54). The final step of peptidoglycan synthesis in Mab is catalyzed by L,D- and D,D-transpeptidases (55). As the relevance of these enzymes in the cell physiology of Mab has not been reported, we limited the scope of the current study to D,D-transpeptidases and initiated a screen to identify a putative D,D-transpeptidase to begin generating insight into this important
Therefore, we are unable to speculate whether the composition of the extracellular matrix can, and phospholipids, when grown in synthetic media representing lung secretions in standard laboratory growth media, as well as extracellular matrix comprised of DNA, glycan, and phospholipids, when grown in synthetic media representing lung secretions in cystic fibrosis patients, have been reported (61–63). As this is the first characterization of Mab lacking Glby, it was beyond the scope of the current study to characterize the composition of the extracellular matrix at the sites of surface meldings between Δglby cells. Therefore, we are unable to speculate whether the composition of the extracellular matrix is similar to or different from what has been described in the literature. We did not observe prominent extracellular matrix in WT and COMP cells. In a screen to probe the source of extracellular DNA, in Mycobacterium avium, reduced levels of extracellular DNA was observed in a mutant with transposon insertion disrupting gene MAVA_03380 which encodes a putative FtsK/SpoIIE (61). FtsK is known to be associated with cell division, whereas FtsI, a domain present in Glby, is known to catalyze peptidoglycan synthesis for cell elongation. It is possible that the loss of Glby function contributes to the increased average cell length of Δglby. Also, the possibility for β-lactam binding activity of Glby could be expected from the presence of this FtsI domain, which is known to exhibit β-lactam binding activity (64), as well as from homology of its protein sequence to that of a (Rv2864c, which is annotated as a PBPs-lipo) (30, 32, 43). Based on the observation that Δglby cells exhibit distinct growth and cell surface morphologies, and the presence of an FtsI-like domain, we hypothesize that Glby may be associated with cell wall function. Although significantly milder than BlaC in β-lactamase activity, Glby was able to hydrolyze a β-lactam probe (Fig. 5). This could not be anticipated from prior literature as proteins containing an FtsI domain are considered to be putative PBPs and therefore a target for inactivation by β-lactams (26, 46).

Our findings also demonstrate that Glby is dispensable for growth in vitro, but its loss significantly increases the generation time of Mab. A recent study based on the generation of a pool of mutants with transposon insertion and detection of outgrowth mutants concluded that glby is likely essential for growth in vitro (58). In this approach, thousands of mutants were generated simultaneously, recovered after outgrowth in a pool, and transposon insertion sites represented in the surviving mutants were identified. The genes disrupted in the mutants in the pool are predicted to be not essential for in vitro growth. This approach is a powerful first screen for prediction of essential genes and has high, but not absolute, accuracy of identifying essential genes (56, 57). Essentiality prediction is based on the lack of detection of a mutant in the pool, which can also include growth impaired mutants, as thousands of other mutants in the pool outgrow impaired mutants and are therefore more
readily detected in the output. Additionally, the possibility that a mutant’s viability or growth is significantly affected in the presence of a complex mutant pool cannot be ruled out. We also demonstrate that specific agitation is required to support growth of Δglby and this could be a potential reason why this strain was not detected in the mutagenesis study. To ascertain if a predicted gene is essential, a direct and site-specific mutagenesis is necessary. Therefore, detection of mutations that attenuate in vitro growth, such as Δglby, is a challenge with transposon based random mutagenesis due to limitations of detection in outgrowth pools. Our findings demonstrate that while Glby is dispensable for in vitro growth, it is required for viability and growth in the lungs of mice. Based on this finding, we hypothesize that Glby is required for Mab to establish a productive infection and cause disease in humans. Despite declumping Δglby cells prior to infecting mice, it is possible that their implantation in the lungs was different from WT and COMP due to potential changes in the cell wall properties. To determine whether the ability of Δglby to form clumps affects their rate of proliferation in the lungs of mice and subsequent disease progression will require additional studies. Based on the clumping and attenuated in vitro growth phenotypes, we hypothesize that cell wall composition of Δglby is altered and these alterations underlie their loss in viability in the lungs of mice.

The 1,046 Mab clinical isolates retrieved from PATRIC represent genotypes with fitness to cause disease in humans. Therefore, Glby sequences in these mutants represent types that likely did not compromise viability or virulence of Mab in humans. In the 1,046 Mab clinical isolates analyzed, none of the SNPs resulted in nonsense mutations that would lead to a truncated Glby, and only one missense mutation with low predicted protein impact. As we were unable to identify any deleterious mutations in Glby in clinical isolates, these data suggest that Glby is likely required for Mab viability in humans as well. One approach toward developing a new therapeutic agent is identification of a protein, or cellular target, in the pathogen that is required for viability or virulence in the host, so that, when inhibited, it can arrest the disease and eventually lead to curing it. Using genetic and microbiological approaches and a mouse model of pulmonary Mab infection, we have provided evidence that biochemical inactivation of pathogenic Mab with an antibiotic specific to Glby has the potential to exhibit bactericidal activity against Mab and improve treatment outcomes.

MATERIALS AND METHODS

Bacterial strains and growth conditions. M. abscessus strain ATCC 19977 (39) was procured from ATCC (Manassas, Virginia), and used as the parent strain, and all strains were derived from it. In general, validated protocols for preparing common reagents for handling and growing mycobacteria were used (65). All strains were grown in Middlebrook 7H9 broth (Difco) supplemented with 10% albumin-dextrose-saline enrichment (ADS), 0.5% glycerol, and 0.05% Tween 80 with constant shaking at 200 rpm in an orbital shaker at 37°C. To culture on solid media, Middlebrook 7H10 agar (Difco) supplemented with 10% ADS and 0.5% glycerol and appropriate antibiotic, depending on the selection required (as noted below), were used. Mab ATCC 19977 exhibited both smooth and rough colony morphotypes on Middlebrook 7H10 agar. The vast majority of the colonies appeared smooth. All inoculations that required agar base were performed on Middlebrook 7H10 with the exception of mouse lung homogenates, which were inoculated onto selective Middlebrook 7H11 agar (Difco) supplemented with 10% ADS, 0.5% glycerol, 20 mg/L Trimethoprim (Sigma-Aldrich, T7683), 50 mg/L Carbencillin (Fisher Scientific, 50-213-247), and 50 mg/L Cycloheximide (Sigma-Aldrich, C7698). E. coli strain DH5α (NEB Labs, C2987H) was used for cloning and E. coli strain BL21(DE3) (NEB Labs, C2527) was used for protein overexpression. These strains were grown in LB Broth as specified by the manufacturer.

Genetic manipulation of Mab. For preparation of electrocompetent cells, Mab strain ATCC 19977 was grown in Middlebrook 7H9 broth to mid-log phase. A subculture in 100 mL of Middlebrook 7H9 supplemented with 0.2% succinate was initiated and monitored until it reached optical density (measured as absorbance at 600 nm, A600) of 0.5 to 0.8 at which point the culture was placed on ice for 30 min and divided into two 50 mL aliquots. These cells were washed four times as follows: the cell suspension was centrifuged at 3,000 rpm for 10 min at 4°C, supernatant was discarded, and the pellet was resuspended in 40 mL ice-cold 10% glycerol. After the final wash, the cell pellet was resuspended in 1 mL 10% glycerol and 200 μL aliquots were transferred into microfuge tubes and stored at −80°C until use.

For genetic manipulation of Mab, electrocompetent ATCC 19977 was transformed with pJV53 in accordance with the recombinering protocol (40). Briefly, Mab competent cells were incubated on ice with ~500 ng of DNA for 10 min and transformation was performed (2.5 kV, 25 μF, 1000 Ω) using an electroporator (Bio-Rad). Cells were recovered in 1 mL of Middlebrook 7H9 broth, incubated for 4 h at 37°C and inoculated onto Middlebrook 7H10 agar supplemented with appropriate antibiotics. For selection of pJV53, 128 μg/mL kanamycin was used, for allelic exchange substrate 64 μg/mL Zeocin and for pMH94-Apra, 25 μg/mL Apramycin was used.
**Glby is Required for M. abscessus Disease**

**Cloning.** All PCRs were carried out using Phusion High Fidelity Polymerase (NEB Labs, M0530). To begin, we PCR amplified Zeo<sup>+</sup> cassette flanked by loxP sites using pMSG360zeo as template (66) and inserted this fragment into pUC19 at the multiple cloning site. Next, we PCR amplified the ~1,500 bp regions from 5’ and 3’ ends of *glby* using PCR and cloned into the flanks of Zeo<sup>+</sup> cassette. This plasmid was used as the template to generate linear allelic exchange substrate spanning 5’-glby-foxP-Zeo<sup>+</sup>-FoxP-3’-glby, pMH94-Apr was generated by replacing Kan<sup>+</sup> cassette from pMH94 (41) with Apr<sup>R</sup> gene cloned from pCAP03-acc3IV (67) using primers that had a complementing overhang with the PCR product from pMH94 (41) for easy restriction cloning.

For overexpression of *Glby*, *glby* was PCR amplified using genomic DNA of Mab strain ATCC 19977 as template and cloned into pET28a + TEV (68). The region in the N-terminus of *Glby* that is predicted to encode a transmembrane anchor domain based on TMHMM (69) and TMPred (70), amino acid residues 1 to 19, was excluded during cloning to facilitate extraction and solubilization of *Glby*. DNA sequences of all resulting plasmids were determined via Sanger sequencing (Eurofins, KY) and only clones with correct sequences were selected for study.

**Protein overexpression and purification.** *Glby* was overexpressed in E. coli BL21 (DE3) cells carrying pET28a- *glby* by inducing a 1- L culture in LB broth with 0.25 mM IPTG overnight at 16°C with orbital shaking at 150 RPM. Without the addition of solubility enhancing additives, *Glby* would exclusively be present in the pellet.

**qDNA extraction, whole genome sequencing, and assembly.** Genomic DNA (gDNA) from all strains was extracted and purified as described for mycobacteria (65). The purity of gDNA preparations were determined spectrophotometrically. Sequences of genomes of WT Mab strain ATCC 19977, *Δglby*, and COMP were determined using Illumina PE150 platform (Novogene, CA, USA). We re-sequenced our stock of WT Mab ATCC 19977 strain to identify pre-existing SNPs with the reference genome of ATCC 19977. The gDNA sequence of our stock of ATCC 19977 was used for comparison with the sequences obtained for *Δglby* and COMP. To verify genotype of *Δglby*, Geneious v11.1.5 (Biomatters) was used to map the sequence reads obtained from gDNA of this strain to the reference strain (Fig. S3). To verify the genotype of the complement strain, *de novo* assembly of the reads was performed, and genes were subsequently annotated in the generated contigs with 100% identity to genes in *Mab* ATCC 19977. Neighboring genes to the *attB* were used to localize the integrated plasmid (Fig. S5).

**Distribution of mutations in Glby in Mab clinical isolates.** Whole genome sequences of 1,046 Mab clinical isolates from around the world that are archived in the PATRIC database (38), including their locations of origin, were considered in our study. Using Geneious v11.1.5 (Biomatters), the sequence of *glby* from all genomes was extracted by creating a custom BLAST database within Geneious. Using ATCC 19977 *glby* as the reference sequence, all 1,046 genomes were queried, and the identified sequences were aligned with the MUSCLE alignment tool included in the software, and a consensus sequence of *glby* was generated (Fig. S1). SNPs and variations in *glby* in each of the 1,046 strains were identified by comparison against the consensus sequence using the “Find Variations/SNPs” algorithm in Geneious. The same method was applied for the mutation distribution of locus MAB_3157c to MAB_3177 and a one-sample t-test was used to determine the P-value for *glby* compared to its surrounding genes.

**Determination of Mab in vitro growth profiles.** Stocks of Mab WT, *Δglby*, and COMP strains, archived in −80°C, were used to inoculate Middlebrook 7H9 broth to generate primary cultures. These cultures were used to inoculate 120 mL Middlebrook 7H9 broth with the same starting OD of A<sub>600</sub> = 0.005. This suspension was used to transfer 2 mL aliquots into 14 mL culture tubes. Four distinct tubes per sample were allocated per time point for each strain and OD was determined by measuring A<sub>600</sub> for 5 days for WT and COMP and 8 days for *Δglby* and CFU were enumerated. *Δglby* CFU required additional 3 days to appear compared to WT and COMP strains and thus the difference of incubation duration.

**Ziehl-Neelsen and Auramine-rhodamine staining.** For both ZN and AR staining stains (44, 45), 60 µL of culture from each strain at exponential phase were placed on a glass slide and allowed to air dry completely. The slides were then passed over the flame of a Bunsen burner for 5 s to heat fix the sample. For ZN stain (Kir–90008-884, BD), carboluffin was applied to cover the smear, heated for 5 s using a Bunsen burner and letting it rest for 5 min. After rinsing the sample with deionized (DI) water, the decolorizer was applied, incubated for 1 min and rinsed again with DI water. The counter stain methylene blue was added to the sample, incubated for 30 s and rinsed with DI water. Once the slides were completely dry, a glass cover slide using Permount mounting medium (SP15-100, Fisher Scientific) was applied. For the AR stain (Kir–212521, BD), the smear was covered with Auramine-rhodamine T for 15 min, after which it was rinsed with DI water. The Decolorizer TM was applied, incubated for 2 min and rinsed with DI water. Finally, potassium permanganate
was applied, incubated for 3 min and rinsed with DI water. Once the slides were completely dried, a glass coverside using Permount mounting medium was applied.

**Nitrocen hydrolysis assay.** Glby, BlaC of *M. tuberculosis* (49, 50), RAD6 (S. cerevisiae), and ubiquitin (human) each at 1.7 μM, were individually mixed with nitrocen (Calbiochem) 100 μM, in 50 mM Tris-Cl buffer pH 8 in a final reaction volume of 100 μL and incubated at 37°C for 6 h. As a control, nitrocen in buffer, but without any protein was included. Hydrolysis of nitrocen was monitored by measuring the absorbance specific to the hydrolyzed product (λmax = 490 nm) (47, 48). To account for the low level of hydrolysis of nitrocen in the buffer itself, the absorbance in the control reaction at each time point was used to correct the absorbance readings in reactions containing protein. Each assay was performed in triplicates.

**Scanning electron microscopy and cell length determination.** Stocks of *Mab* WT, ∆*glby*, and COMP strains, archived in −80°C, were used to inoculate Middlebrook 7H9 broth to generate 3 mL cultures. From each culture, 1.5 mL was taken during exponential phase, and each were fixed in 2.5% glutaraldehyde, 3 mM MgCl2, in 0.05 M sodium cacodylate buffer, pH 7.2 overnight at 4°C. The samples were rinsed with DH2O, and subsequently postfixed in 1% osmium tetroxide in 0.075 M sodium cacodylate buffer for 1 h on ice in the dark. Following another DH2O rinse, samples were dehydrated in a graded series of ethanol and left to dry overnight in a desiccator with hexamethyldisilazane (HMDS). Samples were then mounted on carbon stubs and imaged on a Thermo Fisher Helios Focused Ion Beam Scanning Electron Microscope (FIB-SEM). To measure cell length, we used ImageJ to first set the scale of the image by using the scale bar generated by the microscope software. We used the Freehand line tool to sketch a line between the apex of two poles and parallel to the lateral sides of those cells that were fully and clearly visible and measurements were recorded. Statistical analysis (t-tests) was performed using Microsoft Excel’s data analysis package and a box-and-whisker plot was generated. We manually counted only cells that were clearly visible in our data set and enumerated the melding events to generate percentage of melding events.

**In vivo viability and growth assessment of *Mab***. A mouse model of pulmonary *Mab* infection and the protocol described (51) was used to assess the requirement of Glby for viability and growth of *Mab*. Briefly, C3HeB/FeJ mice, female, 5 to 6 weeks old (Jackson Laboratories, Bar Harbor, Maine), 25 mice per infection group were sacrificed at 1 day (week 0), 1, 2, 3, and 4 weeks following infection, lungs were homogenized, inoculated onto Middlebrook 7H11 selective agar, incubated at 37°C for 5 days for WT and COMP and 8 days for ∆*glby*, and CFU were enumerated. Mean CFU ± standard deviation was calculated to determine the CFU burden of each strain over the time course of the study. Statistical analyses (t-tests) were performed using Microsoft Excel’s data analysis package for each time point for comparisons between infection groups (Table S4).

**Data availability.** The genomics data for clinical strains of *M. abscessus* are available in PATRIC at https://www.patricbrc.org/. The genomics data for strains created in this study are available from the corresponding author upon reasonable request.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1, PDF file, 2.8 MB.**

**ACKNOWLEDGMENTS**

This study was supported by grants R21 AI137720, R01 AI155664 and R01 AI137329. ECM was in part supported by NIH F31 award HL147392. All authors declare no conflict of interest.

G.L. and C.G. conceived and devised the study; C.G. conducted bioinformatics, genetic, cell, and microbiology, and animal studies; C.G. and E.C.M. generated plasmids for genetic manipulation of *M. abscessus*; C.G. and P.K. conducted biochemistry studies; G.L. and C.G. analyzed data, wrote the manuscript; all authors were involved in the manuscript’s revision and finalizing.

**REFERENCES**

1. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. 2010. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 182:970–976. https://doi.org/10.1164/rccm.201002-0310OC.

2. Spaulding AB, Lai YL, Zelazny AM, Olivier KN, Kadri SS, Prevots DR, Adjemian J. 2017. Geographic distribution of nontuberculous mycobacterial species identified among clinical isolates in the United States, 2009–2013. Annals ATS 14:1655–1661. https://doi.org/10.1513/AnnalsATS.201611-860OC.
18. Grif
17. Lopeman RC, Harrison J, Desai M, Cox JAG. 2019. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 27:506–510. https://doi.org/10.1097/QCO.0000000000000104.
16. Jarand J, Levin A, Zhang L, Huijt G, Mitchell JD, Daley CL. 2011. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:565–571. https://doi.org/10.1093/cid/ciq237.
15. Schwartz M, Fisher S, Story-Roller E, Lamanchich G, Parrish N. 2018. Activations of drug combinations of antip against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis. Microb Drug Resist 24:1191–1197. https://doi.org/10.1093/mdr/702.26.
14. Nicklas DA, Maggioncalda EC, Story-Roller E, Eichelman B, Tabor C, Serio AW, Keepers TR, Chitra S, Lamichhane G. 2022. Potency of Omacadymine against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection. Antimicrob Agents Chemother 66: e01742–7021. https://doi.org/10.1128/AAC.01742–21.
13. Nesser R, Cambau E, Reyrat JM, Murray A, Goguel B. 2012. Mycobacterium abscessus: A new antibiotic nightmare. J Antimicrob Chemother 67:810–818. https://doi.org/10.10913/jac/dkr578.
12. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Flore RA. 2017. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72:969–970. https://doi.org/10.1136/thoraxjnl-2017-20929.
11. Schwartz M, Fisher S, Eichelman B, Tabor C, Serio AW, Keepers TR, Chitra S, Lamichhane G. 2022. Potency of Omacadymine against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection. Antimicrob Agents Chemother 66: e01742–7021. https://doi.org/10.1128/AAC.01742–21.
10. Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Moreno P, Merone B, Vial I, Dagle H. 2014. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 27:506–510. https://doi.org/10.1097/QCO.0000000000000104.
9. Jarand J, Levin A, Zhang L, Huijt G, Mitchell JD, Daley CL. 2011. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:565–571. https://doi.org/10.1093/cid/ciq237.
8. Schwartz M, Fisher S, Story-Roller E, Lamanchich G, Parrish N. 2018. Activations of drug combinations of antip against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis. Microb Drug Resist 24:1191–1197. https://doi.org/10.1093/mdr/702.26.
7. Nicklas DA, Maggioncalda EC, Story-Roller E, Eichelman B, Tabor C, Serio AW, Keepers TR, Chitra S, Lamichhane G. 2022. Potency of Omacadymine against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection. Antimicrob Agents Chemother 66: e01742–7021. https://doi.org/10.1128/AAC.01742–21.
6. Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Moreno P, Merone B, Vial I, Dagle H. 2014. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 27:506–510. https://doi.org/10.1097/QCO.0000000000000104.
5. Jarand J, Levin A, Zhang L, Huijt G, Mitchell JD, Daley CL. 2011. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:565–571. https://doi.org/10.1093/cid/ciq237.
4. Schwartz M, Fisher S, Story-Roller E, Lamanchich G, Parrish N. 2018. Activations of drug combinations of antip against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis. Microb Drug Resist 24:1191–1197. https://doi.org/10.1093/mdr/702.26.
3. Benwill JL, Wallace RJ. 2014. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 27:506–510. https://doi.org/10.1097/QCO.0000000000000104.
2. Jarand J, Levin A, Zhang L, Huijt G, Mitchell JD, Daley CL. 2011. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:565–571. https://doi.org/10.1093/cid/ciq237.
1. Schwartz M, Fisher S, Story-Roller E, Lamanchich G, Parrish N. 2018. Activations of drug combinations of antip against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis. Microb Drug Resist 24:1191–1197. https://doi.org/10.1093/mdr/702.26.

36. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, Earle S, Pankhurst LJ, Anson L, Cesare M, Piazza P, Vertinsky AA, Goulakoff T, Wilson DJ, Wylie DH, Diehl R, Niemann S, Feuerriegel S, Kohn TA, Ismail N, Omar SV, Smith EG, Buck D, McKeown G, Walker AS, Petro TEA, Crow DK, Iqbal Z. 2015. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun 6:10063. https://doi.org/10.1038/ncomms10063.

37. Power RA, Parkhill J, de Oliveira T. 2017. Microbial genome-wide association studies: lessons from human GWAS. Nat Rev Genet 18:41–50. https://doi.org/10.1038/nrg.2016.132.

38. Davis JJ, Wattam AR, Azz RK, Brettin T, Butler R, Butler RM, Chlenski P, Conrad N, Dickerman A, Dietrich EM, Gabbard JL, Gerdes S, Guard A, Kenyon RW, Machi D, Mao C, Murphy-Olson D, Nguyen M, Nordberg EK, Olsen GJ, Olson RD, Overbeek JC, Overbeek RA, Pallen BM, Pusch GD, Shukla M, Thomas C, VanOeffelen M, Vonstein V, Warren AS, Xia F, Xie Y, Yoo H, Stevens R. 2019. The PATRIC Bioinformatics Resource Center: expanding data and analysis capabilities. Nucleic Acids Res 48:D606–D612.

39. Moore M, Freericks JB. 1953. An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region. J Invest Dermatol 20:133–169. https://doi.org/10.1007/s11463-019-1353-9.

40. van Kessel JC, Hartfall GF. 2008. Mycobacterial recombinering. Methods Mol Biol 435:203–215. https://doi.org/10.1007/978-1-59745-232-8_15.

41. Lee MH, Pascopella L, Jacobs WR, Hatfull GF. 1991. Site-specific integration of mycobacteriophage L5: integration-point vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc Natl Acad Sci U S A 88:3111–3115. https://doi.org/10.1073/pnas.88.8.3111.

42. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215:403–410. https://doi.org/10.1016/S0022-2836(05)80360-2.

43. Koppoulou A, Lew JM, Cole ST. 2011. The Mycobrowser portal: A comprehensive and manually annotated resource for mycobacterial genomes. Tuberculosis (Edinb) 91:9–13. https://doi.org/10.1016/j.tube.2010.09.006.

44. Bishop PJ, Neumann G. 1970. The history of the Ziehl-Neelsen stain. Tuber Lung Dis 51:196–206. https://doi.org/10.1007/978-94-010-09073-5.

45. Somoskovi A, Hataling JE, Fitzgerald M, O’Donnell D, Parsons LM, Saffinger M. 2001. Lessons from a proficiency testing event for fast-aacid microscopy. Chest 120:250–257. https://doi.org/10.1378/chest.120.1.250.

46. Kaczmarek FS, Gootz TD, Dib-Haj F, Shang W, Hallowell S, Cronan M. 2004. Genetic and molecular characterization of β-lactamase-negative ampicillin-resistant haemophilus influenzae with unusually high resistance to ampicillin. Antimicrob Agents Chemother 48:1630–1639. https://doi.org/10.1128/AAC.48.6.1630-1639.2004.

47. O’Callaghan CH, Morris A, Kirby SM, Shingler AH. 1972. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1:283–288. https://doi.org/10.1128/AAC.1.4.283.

48. Chow C, Xu H, Blanchard JS. 2013. Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from mycobacterium tuberculosis. Biochemistry 52:4097–4104. https://doi.org/10.1016/j.biocel.2012.04.017.

49. Wang F, Cassidy C, Sacchetini JC. 2006. Crystal structure and activity studies of the Mycobacterium tuberculosis β-lactamase reveal its critical role in resistance to-lactam antibiotics. Antimicrob Agents Chemother 50:2762–2771. https://doi.org/10.1128/AAC.00320-06.

50. Tremblay LW, Hugonnet JE, Blanchard JS. 2008. Structure of the covalent adduct formed between Mycobacterium tuberculosis β-lactamase and clavulan. Biochemistry 47:5312–5316. https://doi.org/10.1021/bi0701055.

51. Maggiorinacalda EC, Story-Roller E, Mylius J, Iller P, Basaraba JR, Lamichhane G. 2020. A mouse model of pulmonary Mycobacteroides abscessus infection. Sci Rep 10:1–8. https://doi.org/10.1038/s41598-020-60452-1.

52. Story-Roller E, Maggiorinacalda EC, Lamichhane G. 2019. Synergistic efficacy of β-lactam combinations against mycobacterium abscessus pulmonary infection in mice. Antimicrob Agents Chemother 63:e00414-19. https://doi.org/10.1128/AAC.00414-19.

53. Crick DC, Pavelka MS, Jr, Mahapatra S. 2014. Genetics of peptidoglycan biosynthesis. Microbiol Spectr 2(MGM2)–20. https://doi.org/10.1128/microbiolspec. MGM2-00034-2013.

54. Hamad B. 2010. The antibiotics market. Nat Rev Drug Discov 9:675–676. https://doi.org/10.1038/nrd3267.